Takeda verkoopt luchtwegenportfolio aan AstraZeneca
OSAKA, Japan–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited heeft vandaag een definitief akkoord bereikt met AstraZeneca over de verkoop van zijn portfolio met producten voor luchtwegen en ademhaling. Takeda formuleerde vier focusgebieden in 2014: gastro-enterologie, oncologie, het centraal zenuwstelsel, hart en vaten en stofwisseling. De afstoting stelt Takeda in staat de beste in zijn klasse te worden in deze kernrichtingen, terwijl de continuïteit van de patiëntenzorg gewaarborgd blijft.
“Patiënten vormen de primaire focus van Takeda en we spannen ons in voor een nauwe samenwerking met AstraZeneca, zodat we een soepele overgang kunnen garanderen”, zei ceo van Takeda Christophe Weber. “AstraZeneca heeft uitgebreide ervaring in behandelingen aan de luchtwegen en is in staat deze belangrijke medicijnen te bezorgen bij de patiënten die ze nodig hebben.”
Takeda Announces Sale of Respiratory Portfolio to AstraZeneca |
|||||
|
OSAKA, Japan–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced that it has entered into a definitive agreement to sell its respiratory portfolio to AstraZeneca. In 2014 Takeda defined four therapeutic areas of focus: Gastroenterology, Oncology, Central Nervous System, and Cardiovascular and Metabolic. This divestiture will allow Takeda to work on becoming best-in-class in these therapeutic areas, while maintaining continuity of care for patients. “Patients are Takeda’s primary focus and we are committed to working closely with AstraZeneca to ensure a smooth transition,” said Christophe Weber, Chief Executive Officer, Takeda Pharmaceutical Company Limited. “AstraZeneca has extensive experience in respiratory care and will be able to prioritize getting these important medicines to the patients that need them.” Under the terms of the agreement, AstraZeneca will acquire the respiratory business including products Daxas (roflumilast), Alvesco and Omnaris (ciclesonide). The acquisition will also include regional and local products, as well as several pre-clinical assets. A number of Takeda employees will transfer to AstraZeneca upon completion of the divestiture. The financial impact from this divestiture on Takeda’s 2015 consolidated financial statements is expected to be minimal. Sales of respiratory products, Daxas, Alvesco and Omnaris, totaled approximately 24 billion yen in fiscal year 2014. The transaction is expected to close during the first calendar quarter of 2016, subject to customary closing conditions. About Takeda Pharmaceutical Company Limited View source version on businesswire.com: http://www.businesswire.com/news/home/20151216005425/en/ Contacts Media Contacts: |
|||||